Cargando…
The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients
Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot s...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/ https://www.ncbi.nlm.nih.gov/pubmed/33799535 http://dx.doi.org/10.3390/medicina57030257 |
_version_ | 1783670478457536512 |
---|---|
author | Tirnea, Livius Bratosin, Felix Vidican, Iulia Cerbu, Bianca Turaiche, Mirela Timircan, Madalina Margan, Madalin-Marius Marincu, Iosif |
author_facet | Tirnea, Livius Bratosin, Felix Vidican, Iulia Cerbu, Bianca Turaiche, Mirela Timircan, Madalina Margan, Madalin-Marius Marincu, Iosif |
author_sort | Tirnea, Livius |
collection | PubMed |
description | Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients. |
format | Online Article Text |
id | pubmed-7998120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79981202021-03-28 The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients Tirnea, Livius Bratosin, Felix Vidican, Iulia Cerbu, Bianca Turaiche, Mirela Timircan, Madalina Margan, Madalin-Marius Marincu, Iosif Medicina (Kaunas) Article Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients. MDPI 2021-03-11 /pmc/articles/PMC7998120/ /pubmed/33799535 http://dx.doi.org/10.3390/medicina57030257 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Tirnea, Livius Bratosin, Felix Vidican, Iulia Cerbu, Bianca Turaiche, Mirela Timircan, Madalina Margan, Madalin-Marius Marincu, Iosif The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title | The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title_full | The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title_fullStr | The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title_full_unstemmed | The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title_short | The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients |
title_sort | efficacy of convalescent plasma use in critically ill covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998120/ https://www.ncbi.nlm.nih.gov/pubmed/33799535 http://dx.doi.org/10.3390/medicina57030257 |
work_keys_str_mv | AT tirnealivius theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT bratosinfelix theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT vidicaniulia theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT cerbubianca theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT turaichemirela theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT timircanmadalina theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT marganmadalinmarius theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT marincuiosif theefficacyofconvalescentplasmauseincriticallyillcovid19patients AT tirnealivius efficacyofconvalescentplasmauseincriticallyillcovid19patients AT bratosinfelix efficacyofconvalescentplasmauseincriticallyillcovid19patients AT vidicaniulia efficacyofconvalescentplasmauseincriticallyillcovid19patients AT cerbubianca efficacyofconvalescentplasmauseincriticallyillcovid19patients AT turaichemirela efficacyofconvalescentplasmauseincriticallyillcovid19patients AT timircanmadalina efficacyofconvalescentplasmauseincriticallyillcovid19patients AT marganmadalinmarius efficacyofconvalescentplasmauseincriticallyillcovid19patients AT marincuiosif efficacyofconvalescentplasmauseincriticallyillcovid19patients |